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Abstract
High dimensional case control studies are ubiquitous in the biological sciences, particularly ge-
nomics. To maximise power while constraining cost and to minimise type-1 error rates, researchers
typically seek to replicate findings in a second experiment on independent cohorts before proceeding
with further analyses.
This paper presents a method in which control (or case) samples from the discovery cohort
are re-used in the replication study. The theoretical implications of this method are discussed and
simulations used to compare performance against the standard method in a range of circumstances.
In several common study designs, a shared-control method allows a substantial improvement in
power while retaining type-1 error rate control.
An important area of potential application arises when control samples are difficult to recruit
or ascertain; for example in inter-disease comparisons, or studies on degenerative diseases. Using
similar methods, a procedure is proposed for ‘partial replication’ using a new independent cohort
consisting of only controls. This methods can be used to provide some validation of findings when
a full replication procedure is not possible.
The new method has differing sensitivity to confounding in study cohorts compared to the
standard procedure, which must be considered in its application. Type-1 error rates in these
scenarios are analytically and empirically derived, and an online tool for comparing power and
error rates is provided.
Although careful consideration must be made of all necessary assumptions, this method can
enable more efficient use of data in genome-wide association studies (GWAS) and other applications.
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Introduction
High-dimensional case-control studies have become a mainstay of investigation of pathophysiology
in complex diseases and traits. An important part of their analysis is the process of replication [1],
in which the results of a high-dimensional study are used to inform the design of a second study at
a subset of the original variables, with a joint analysis used to determine overall association.
Replicating studies in this way has the advantage of increasing the effective study sample sizes
without requiring measurement of all variables in all samples. It also serves to protect against
false-positives due to systematic errors in the original datasets, by re-testing association in a second
nominally independent dataset.
Replication has a significant cost, and can require large numbers of samples, especially when
associated variables have small effects (ie [2]). There is therefore a need to minimise the num-
ber of additional samples which need to be analysed. This paper presents a method to perform
replication by combining controls in both the original ‘discovery’ and second ‘replication’ datasets,
potentially reducing the number of new samples required. Shared-control approaches can improve
study efficiency in many related applications in which studies are compared [3, 4, 5, 6, 7, 8].
Results from original and replication datasets for which some or all controls are shared cannot
be directly compared due to the correlation between test statistics directly resulting from shared
controls even under the null hypothesis [5]; use of the same thresholds in a shared-control design as
used in an independent-controls design will lead to higher type-1 error rates. This paper demon-
strates a simple adaptation to a standard design to account for the changed correlation structure
and retain control of type-1 error rate, only requiring a change to one p-value threshold.
The action of sharing control samples results in a different spectrum of sensitivity to confound-
ing in study groups. It necessitates a sacrifice of type-1 error rate control in variables affected
by confounding in the discovery-phase control cohort, but improves type-1 error rate control in
variables affected by confounding in the replication-phase control cohort. Performance is largely
equivalent to an independent-controls design for variables affected by confounding in either case
cohort.
The new spectrum of false positive rates can be advantageous in circumstances where control
samples in the replication cohort are less well-ascertained than those in the discovery cohort. This
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may be the case in studies on degenerative disease, where control ascertainment is generally un-
certain, and population-sourced controls may be used for replication. The shared-control design
can reduce power losses from mis-specified controls in the replication cohort, as well as reducing
false-positive rates caused by confounding in the cohort.
When used with shared cases instead of controls, this method can be adapted to a ‘partial
replication’ procedure where only a new control set is used. Although not equivalent to a full
replication in an independent dataset, the procedure enables improvement in type-1 error rates and
control over confounding. This is applicable in studies on rare traits, where all available samples
need to be included in the discovery analysis for adequate power.
Throughout this paper, GWAS terminology will be used (SNPs, allele frequency, variants etc)
although the method is applicable to any high-dimensional case control study. ‘Controls’ will be
considered to generally be samples unaffected by a disease or trait of interest, although the method
can be applied with case/control labels swapped, or applied to comparisons between subgroups of
a case group. Asymptotic analytical results are established where possible, but all type 1/type 2
error rates are readily tractable empirically to good accuracy given study sizes and proposed p-
value thresholds, and a tool is provided to do this at https://wallacegroup-liley.shinyapps.
io/replication_shared/.
Results
Overview of method
We assume a GWAS dataset of a set of cases C1 and controls C0 used in a ‘discovery’ phase of
a GWAS or similar study, and corresponding sets of cases and controls C ′1, C ′0 in the replication
phase. We assume that C0 and C1 are genotyped at a set of SNPs S and C
′
0, C
′
1 at a set S
′ ⊆ S.
For each SNP we designate µ1, µ0, µ
′
1, µ
′
0 as the population minor allele frequency in the
corresponding group, and m1, m0, m
′
1, m
′
0 as the observed allele frequency (so E(mi) = µi). We
designate two null hypotheses; H∪0 : (µ1 = µ0) ∪ (µ′1 = µ′0) and H∩0 : (µ1 = µ0 = µ′1 = µ′0), noting
that H∪0 ⊇ H∩0 . In a typical conservative GWAS approach, we seek to test against H∪0 , since
µ1 6= µ0 or µ′1 6= µ′0 may hold at non-disease associated SNPs due to confounding in the original or
replication studies respectively.
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A typical two-stage genetic testing procedure [1], which we will refer to as method A, begins
by comparing genotypes of C1 and C0 at SNPs S generating p-values pd (discovery). A subset S
′
of SNPs reaching putative significance level pd < α are genotyped in C
′
0 and C
′
1, with genotypes
compared to generate p-values pr (replication stage). Finally, genotypes are compared between
C0∪C ′0 and C1∪C ′1 at SNPs S′ to generate p-values pm (meta-analytic stage). SNPs are designated
as ‘hits’ if pd < α, pr < β, pm < γ for some β, γ, and all effects have the same direction.
The main modification proposed in this paper, denoted as method B, differs at the replication
stage in that C ′1 is compared with C0 ∪ C ′0 at S′ instead of just C ′0. The p-values resulting from
the modified replication stage are termed ps, and the criterion to designate a hit changed to pd <
α, ps < β
∗, pm < γ, with all effects in the same direction. The threshold β∗ is chosen to conserve
type-1 error rate between methods (see methods section, appendix 1.1).
A second modification, denoted method C, combines C0 and C
′
0 at both the discovery and
replication phase. This is analagous to a situation in which only a single control cohort is available,
and a choice must be made to split it between discovery and replication procedures or to use it for
both. In this case, C0 ∪ C ′0 is compared with C1 at SNPs S in the discovery phase to produce p-
values pc, then C0∪C ′0 is compared with C ′1 at SNPs S′ at the replication phase and compared with
C1 ∪ C ′1 at the meta-analytic stage to produce p-values ps and pm as before. A hit is determined
by pd < α, ps < β
⊥, pm < γ, with all effects in the same direction. Again, β⊥ is chosen to maintain
the type-1 error rate between methods.
General properties
For SNPs in H∩0 , the overall type-1 error rate is conserved between methods by the definition of
β∗, β⊥ (equation 2) at a level P0. It is shown in appendix 1.2.2 that β > β∗ > β⊥. For SNPs
in H∪0 \ H∩0 the type-1 error rates differ between methods. Such SNPs may be characterised by
the group(s) amongst C0, C1, C
′
0, C
′
1 in which their expected MAF is aberrant from the expected
MAF in the population which the group ostensibly represents. ‘Aberrance’ is taken to mean an
incorrect expected value from systematic measurement error or uncorrected confounding, rather
than random deviance around a correct expected value.
Bounds on type-1 error rates with aberrance in each group are shown in table 1. Methods B
and C necessitate sacrificing bounds on error rates with aberrance in C0 and C0,C
′
0 respectively.
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Figure 1: Diagram of methods A, B, and C. Method B differs by comparing C ′1 to pooled C0 and
C ′0 at the replication stage to generate p-value Ps instead of Pr. Method C also pools controls at
the discovery phase, comparing C1 to pooled C0 and C
′
0 to generate p-values Pc instead of Pd. A
‘hit’ is declared in method A if Pd < α, Pr < β, Pm < γ, in method B if Pd < α, Ps < β
∗, Pm < γ
and in method C if Pc < α, Ps < β
⊥, Pm < γ.
The bound on error with aberrance in C ′1 improves through methods A-C. In the methods section,
it is shown that the type-1 error with aberrance in C ′0 decreases from methods A to B, and the
error with aberrance in C ′1 increases from A through C, although the upper bound is the same for
both.
Table 1: Upper bounds on type 1 error rates with aberrance in cohorts, with β > β∗ > β⊥
Aberrant
None C0 C
′
0 C1 C
′
1
M. A P0 β α β α
M. B P0 1 α β
∗ α
M. C P0 1 1 β
⊥ α
Simulation
The power difference between methods B and A was analysed systematically across a range of
values of (n0, n1, n
′
0, n
′
1). Average power difference and maximum power difference were compared
(see methods section). Figure 2 shows power difference at various study sizes for typical α, β, γ
values (α = 5× 10−6, β = 5× 10−4, γ = 5× 10−8) and minor allele frequency 0.1. The difference
is typically highest when the ratio of controls to cases is high in the discovery cohort and low or
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equal in the replication cohort, and the number of cases in the discovery cohort is larger than the
number in the replication cohort. Power to detect SNPs in H1 is typically highest in method C,
second-highest in method B, and lowest in method A.
Recommended applications
To demonstrate areas where this approach is applicable, several examples are constructed or sourced
from the GWAS field in which the procedure of sharing controls or cases will improve power or
type-1 error profile of the two-stage testing procedure or enable some form of orthogonal replication
to be performed.
Assumptions
In order to use method B or C, it must be assumed that cohort C0 and C
′
0 are sampled from
similar enough populations to be comparable to C1 and C
′
1 (possibly with the inclusion of strata or
covariates in the genetic risk model). An important caveat of methods B and C is sacrifice of control
over errors arising from aberrance in C0 (method B) or C0 ∪ C ′0 (method C), so an assumption
must be made that variables affected by confounding or measurement error in these cohorts are
understood to be distinguishable from true associations by quality-control measures only.
Post-hoc assessment of all putative hits should be performed to check for genotyping errors [9]
and assess whether the hit could have arisen from aberrance in C0.
Conventional GWAS
Method B is applicable in several cases in large conventional GWAS, particularly when then ratio of
controls to cases in the discovery cohort is larger than that in the replication cohort. In a relatively
recent GWAS on rheumatoid arthritis [10] with comparable sample populations for discovery and
replication cohorts, method B could be used to attain greater power than method A for a fixed
type-1 error rate. Assuming that summary statistics are well-approximated by binomial tests of
allelic differences (so covariates and strata used in computation of summary statistics have only
small effects), the improvement in power is around 4% for SNPs with an odds-ratio of 1.3, MAF 0.1,
and is positive across all odds ratios. More than 2000 additional controls in C ′0 would be needed
to increase power by this amount (figure 3a).
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Figure 2: General power differences (%) between methods A and B. Mean power difference is taken
as the integral of power difference between methods B and A (see methods section) over R with
respect to log-odds ratio. In all cases, 20 000 samples are used overall for a SNP with MAF 0.1,
with cutoffs α = 5× 10−6, β = 5× 10−4, γ = 5× 10−8.
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Small power advantages such as this may make minimal difference in a single study, although
since they require no extra cost, are worth attaining if possible. The power of method B is generally
considerably higher than method A when n0 > n1 and n
′
0 ≈ n′1, Power advantages may be more
substantial in some cases; for example, a study with (n0, n1, n
′
0, n
′
1) = (15000, 5000, 5000, 5000),
method B enables a power increase of up to 8% (Figure 3b). To achieve comparable performance
with method A, around 2000 additional controls would be necessary in the replication cohort.
Method B with (n0, n
′
0) = (15000, 5000) is also more powerful than method A would be if controls
were divided equally between C0 and C
′
0 (see Figure 3b).
Difficult control ascertainment
An important application of the method presented in this paper is in studies for which ‘control’
samples are expensive or difficult to ascertain. This is often the case in comparative studies between
disease subtypes. In such studies, sharing controls can improve power substantially, especially if
a proportion of samples in the replication cohort are falsely assigned to the control cohort (see
methods section).
An international GWAS on fronto-temporal dementia in 2014 [11] is an example in which sharing
controls may be beneficial. The study had sample sizes (n0, n1, n
′
0, n
′
1) = (4308, 2154, 5094, 1372).
Control samples in the discovery phase were assessed for current neurological disease, and were used
in previous studies on Parkinson’s disease, indicating a high degree of reliability. Control samples
in the replication phase were collected from the same geographic distribution as cases, but were not
explicitly used in previous neurological studies, suggesting better control ascertainment amongst
the discovery cohort.
In this study, sharing controls could allow for a more strongly-ascertained control cohort, and
reduce the effects of confounders affecting C ′1. At typical values α = 1 × 10−4, β = 1 × 10−3,
γ = 5 × 10−8, power is nearly equivalent between the two methods assuming all controls are
genuine. However, with 10% misascertainment in C ′1, the power advantage of method B is up to
5%. Given the near-identical distribution of cases in the discovery and validation cohort, cases
could alternatively be shared, leading to a power increase of up to 6%.
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Prospective study design
Studies may be planned and powered with the assumption that samples may be shared. For
certain restrictions on sample numbers, this can provide the potential for greater power than would
be attainable by restricting to an independent-controls design. For instance, if we seek to validate
hits on a GWAS with 10000 controls and 5000 cases, and can afford to genotype a further 10000
samples, power is higher after recruiting 4000 additional controls and 6000 additional cases and
sharing controls than can be achieved from any independent-control study design (Figure 3d).
This may be a common scenario if controls are sourced from a known database rather than
specifically recruited for the study.
Partial replication
In circumstances where case recruitment is difficult, as in studies of rare diseases, an assessment of
replicability may be made by re-testing results from a discovery phase with a new control set only.
This can enable the use of control cohorts which only partially match the case cohort.
In a GWAS on pemphigus vulgaris [12], a rare disease primarily affecting individuals of Ashke-
nazi Jewish ethnicity, the discovery cohorts were sampled from Jewish populations, with age- and
population- matched controls. Control cohorts were small ((n0, n1, n
′
0, n
′
1) = (100, 400, 59, 285)),
potentially due to difficulty recruiting both ethnically- and geographically-matched controls.
Method C could be used in this instance to enable a larger control set and greater power. If a
control cohort of Ashkenazi individuals could be assembled without requiring geographic matching
with the case set, it would be inappropriate to use as a sole control cohort against the existing case
cohort, due to the potential for geographic confounding. However, such a cohort could be used as
either C0 or C
′
0 in method C, with the existing ethnically- and geographically- matched controls
serving as the other cohort. In this way, the power advantage of the larger cohort could be used
while maintaining control over potential aberrance in the larger control group.
Method C enables computation of power and type-1 error rates, and comparison to alternative
designs with cases split into smaller independent discovery and validation cohorts (method A).
Testing a case cohort against two separate control cohorts is almost always more powerful for
a fixed type-1 error rate than splitting the case cohort in two and performing method A (see
10
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Figure 3: Examples of comparison of power of methods A and B. In all panels, a positive
odds ratio corresponds to a deleterious mutation and average MAF is 10%. The top two pan-
els show comparisons of method B with n′0 fixed against method A with varying n′0. Panel 3a
has (n0, n1, n
′
0, n
′
1) = (20169, 5539, 8806, 6768) (values from a GWAS on RA [10]), and panel 3b
(n0, n1, n
′
0, n
′
1) = (15000, 5000, 5000, 5000). Both panels use (α, β, γ) = (5×10−6, 5×10−4, 5×10−8).
Panel 3c demonstrates the effect of false-ascertainment (F.A) in C ′0; when cases are mis-ascertained
as controls. In this case, (α, β, γ) = (1× 10−4, 1× 10−3, 5× 10−8), reflecting values used in the pa-
per [11]. Panel 3d demonstrates a prospective scenario with 10000 samples for replication. Method
B with (n0, n1) as above, (n
′
0, n
′
1) = (4000, 6000) is more powerful than any design using method
A (grey region; n′0 ∈ (1000, 9000); n′1 = 10000− n′0).
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supplementary figures 5,6).
Discussion
This paper proposes a method to improve efficiency of data use in a replication procedure, adding
to the body of methods for comparison of high-dimensional case-control studies. For many com-
mon study sizes, the method can reduce the cost of replication, or increase power of discovery. The
adapted method is simple to apply, only requiring modification of a single association threshold.
A standard replication procedure (or more general comparison of case-control studies) with inde-
pendent control datasets does not make use of the information that expected values of variables in
control datasets are, in principle, the same. In this way, the same dataset can in theory yield more
information when controls are shared.
The most important caveat of these methods is the loss of systematic type-1 error rate control
for null SNPs which are aberrant in C0. Control of such errors must not be sacrificed entirely, but
in some circumstances it may be satisfactory to assess such errors on a SNP-by-SNP basis. Such
assessment is important and standard for all proposed GWAS hits under any method [13] in the
interests of quality control. In method C, control over aberrance in C ′0 is additionally lost; however,
since this method is largely applicable when C0∪C ′0 is a single homogenous control (or case) cohort,
there is no way that aberrance in the cohort can be systematically identified by comparison with
other cohorts.
Somewhat better control of the type-1 error rate can often be achieved for SNPs with aberrance
in C1 or C
′
0. This may incentivise the use of this method when confidence in the representativeness
of these cohorts is low compared to that of C0. The type 1 error rate is somewhat increased for
SNPs with aberrance in C ′1, although as it remains bounded by α, this increase is not a major
problem.
The two-stage validation procedure is similar to a meta-analysis of the discovery and validation
experiments, for which several adaptations to shared-control designs have been proposed [3, 4].
However, there are several important distinctions which necessitate an alternative approach in this
case. Firstly, not all variables are measured in the second (replication) study; we are restricted
to analysis of variables reaching a given observed effect size. Secondly, the studies to be ‘meta-
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analysed’ are not complete, in the sense that there may be residual confounding; a strong effect size
in the meta-analysis alone is not adequate evidence for association and some level of association
(with consistent direction) is additionally required in both constituent studies.
The method is inapplicable when replication is performed on cohorts from completely distinct
geographic groups, although there can be some difference in geographic distribution between control
sets if this is controlled for in computing summary statistics. The method is most applicable when
control groups are sampled from similar populations and genotyped on similar platforms.
The widespread discoveries of the GWAS field have led to corresponding increases in complexity
of phenotypic definitions, with ever-finer delineations of disease types of ever-rarer prevalence.
The genetic analysis of such complex phenotypes is necessarily comparative; there is little use
understanding the genetics of a rare disease subtype except in the context of the genetics of the
disease in general. Such analyses necessitate GWAS and other comparative studies between rare
phenotypic types [14], with ‘controls’ meaning the better-characterised disease subphenotype in
this sense, as well as between cases and controls. Rare disease subtypes are often afflicted with
ascertainment difficulties, leading to varying degrees of expected aberrance in disease cohorts.
Within this paradigm, the applicability of this method is likely to expand.
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Methods
Definitions
Denote zx for x ∈ {d, r, s,m, c} as the signed z-score (±Φ−1(px/2)) corresponding to px, and zx
for x ∈ α, β, β∗, γ as the positive corresponding threshold −Φ−1(x/2), where Φ,Φ−1 are the stan-
dard normal CDF and quantile functions. Other than (zd, zr), all pairs of z-scores are correlated
under H∩0 , with correlation estimable from sample sizes or empirically if covariates are used (Ap-
pendix 1.1). Denote ρxy as the correlation between zx and zy, (x, y) ∈ {d, r, s,m}2, and set
ΣA = var
(
(zd zr zm)
t
)
ΣB = var
(
(zd zs zm)
t
)
ΣC = var
(
(zc zs zm)
t
)
(1)
For i ∈ {d, r, s,m, c} define ζi = E(zi), where the expectation is conditional on the SNP in question.
For SNPs in H∩0 , ζi ≡ 0, but this may not hold for SNPs in H∪0 \ H∩0 . In theoretical working,
aberrance in groups is characterised by values ζi rather than log-odds ratios, noting that the values
ζi are asymptotically proportional to the corresponding log-odds ratios. Define RA, RB, RC as the
false-positive rates for a SNP of interest in methods A, B and C respectively.
General type 1 error rate
The values β∗, β⊥ are chosen to satisfy
2
∫ ∞
zα
∫ ∞
zβ∗
∫ ∞
zγ
NΣB
(
zd
zr
zm
)
dzmdzrdzd = 2
∫ ∞
zα
∫ ∞
z
β⊥
∫ ∞
zγ
NΣC
(
zd
zr
zm
)
dzmdzrdzd
= 2
∫ ∞
zα
∫ ∞
zβ
∫ ∞
zγ
NΣA
(
zd
zr
zm
)
dzmdzrdzd
= Pr(pd < α, pr < β, pm < γ|H∩0 ) (2)
thus conserving the type 1 error rate (denoted P0) against H
∩
0 between methods (Figure 4). If no
threshold is used on pm (ie, γ = 1), then β
∗, β⊥ satisfy
Pr(pd < α, ps < β
∗|H∩0 ) = Pr(pc < α, ps < β⊥|H∩0 ) = Pr(pd < α, pr < β|H∩0 ) = αβ (3)
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since zd ⊥ zr|H∩0 . Definition 2 will be considered a generalisation of definition 3, with results
established first for β∗ as per definition 3 and extending where possible to definition 2.
For β∗ defined as per definition 3 we have (see Appendix 1.2.1)
lim
zα→∞
zβ∗√
1− ρ2dszβ + ρdszα
= 1 lim
zα→∞
zβ⊥√
1− ρ2cszβ + ρcszα
= 1 (4)
approaching from above, so zβ∗ > max
(
zβ,
√
1− ρ2dszβ + ρdszα
)
, zβ⊥ > max
(
zβ,
√
1− ρ2cszβ + ρcszα
)
.
As defined by equation 3, zβ∗ , zβ⊥ are also asymptotically linear in zα, zγ , zβ as the former two tend
to ∞, with some constraints (Appendix 1.2.1), although the limit does not necessarily approach
from above. For both definitions, β⊥ < β∗ < β (Appendix 1.2.2)
Study sizes, odds ratios and allele frequencies
Consider a study with n0 controls and n1 cases, with underlying allele frequencies µ0 and µ1 in
cases and observed allele frequencies m0, m1. Let Z be a signed Z-score derived from a GWAS
p-value against the null hypothesis µ0 = µ1. To first order,
E(Z) =
√
2n0n1
n0 + n1
µ1 − µ0√
µ¯(1− µ¯) (5)
where µ¯ = n0µ0+n1µ1n0+n1 . Hence
ζd =
√
2n0n1
n0+n1
µ1−µ0√
µ¯(1−µ¯) ζr =
√
2n′0n
′
1
n′0+n
′
1
µ′1−µ′0√
µ¯(1−µ¯)
ζs =
√
2(n0+n′0)n
′
1
n0+n′0+n
′
1
µ′1−
µ0n0+µ
′
0n
′
0
n0+n
′
0√
µ¯(1−µ¯) ζc =
√
2(n0+n′0)n1
n0+n′0+n1
µ1−µ0n0+µ
′
0n
′
0
n0+n
′
0√
µ¯(1−µ¯)
ζm =
√
2(n0+n′0)(n1+n
′
1)
n0+n′0+n1+n
′
1
µ1n1+µ
′
1n
′
1
n1+n
′
1
−µ0n0+µ
′
0n
′
0
n0+n
′
0√
µ¯(1−µ¯) (6)
where µ¯ varies between definitions (though it is sometimes taken to be approximately equal). These
formulae allow ζi to be estimated in empirical computations. Estimation of ζi is more complex if
covariates or strata are used in the computation of zi (appendix 1.1).
In all empirical computations, systematic allelic differences (whether due to aberrance or true
association) are characterised by odds ratios and minor allele frequency rather than ζi. Values µ0
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and µ1 (in general terms) are readily computable from odds-ratios R =
µ1(1−µ0)
µ0(1−µ1) and minor allele
frequency µ = µ0+µ12 . The use of this characterisation of minor allele frequency (rather than the
‘weighted’ characterisation n0µ0+n1µ1n0+n1 ) is so that the correspondence between (R,µ) and (µ0, µ1) is
independent of n0, n1; for instance, for a disease-associated variant satisfying µ1 = µ
′
1, µ0 = µ
′
0 will
have identical odds ratios µ1(1−µ0)µ0(1−µ1) and
µ′1(1−µ′0)
µ′0(1−µ′1) between the discovery and validation experiments,
but generally different weighted MAFs n0µ0+n1µ1n0+n1 and
n′0µ
′
0+n
′
1µ
′
1
n′0+n
′
1
.
False ascertainment
In general, for a true association, µ0 = µ
′
0 and µ1 = µ
′
1. If some proportion κ of samples in C
′
0 are
incorrectly assigned and come from the case population, then µ′0 = (1 − κ)µ0 + κµ1. This lowers
the absolute values of ζr, ζs and ζm, reducing the power to detect the SNP.
Empirical computations
Define NΣ(z) as the pdf of the multivariate normal with mean 0 and variance Σ at z. Determination
of covariance is described in Appendix 1.1. Given ζd, ζr, ζs, ζm, the probability of rejecting the
null for a given SNP using method A is
∫ ∞
zα−ζd
∫ ∞
zβ−ζr
∫ ∞
zγ−ζm
NΣA
(
(zd zr zm)
t
)
dzmdzrdzd
+
∫ ∞
zα+ζd
∫ ∞
zβ+ζr
∫ ∞
zγ+ζm
NΣA
(
(zd zr zm)
t
)
dzmdzrdzd (7)
and using method B
∫ ∞
zα−ζd
∫ ∞
zβ−ζs
∫ ∞
zγ−ζm
NΣB
(
(zd zs zm)
t
)
dzmdzsdzd
+
∫ ∞
zα+ζd
∫ ∞
zβ+ζs
∫ ∞
zγ+ζm
NΣB
(
(zd zs zm)
t
)
dzmdzsdzd (8)
If n0n1 =
n′0
n′1
, matrix ΣA is singular (Appendix 1.1), in which case zm = ρdmzd + ρvmzv and the
expression above may be reduced to a two-dimensional integral over a more complex region (Fig-
ure 4). Matrix ΣC is generally singular, so the formula zm =
ρcsρsm−ρcm
ρ2cs−1 zd +
ρcsρcm−ρsm
ρ2cs−1 zs is used
to reduce the integral in a similar way. A similar formula may be used if ΣB is nearly singular.
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In Figure 2, mean power difference is determined as the integral of the power difference with
respect to the log-odds ratio over the real line.
Type 1 error rates
Aberrance in C1
For SNPs aberrant in only C1 we have ζd 6= 0, ζc 6= 0, ζm 6= 0, and ζr = ζs = 0.
RA, RB, RC can be considered as functions of ζd. As ζd → 0, RA, RB, RC → P0 (equation 2).
As ζd → ±∞, RA → β2 , RB = β
∗
2 and RC =
β⊥
2 . For positive ζd both RA and RB are increasing
(and both are symmetric in ζd) so RA <
β
2 , RB <
β∗
2 , RC <
β⊥
2 for all ζd.
Since β⊥ < β∗ < β (often substantially), methods B and C are generally better at rejecting H∩0
for such SNPs. In the simplified case where zγ = 1, RA ≥ RB universally (Appendix 1.3.1. This
typically holds for all zγ , except for small deviations in pathological cases.
In general, we consider aberrance which is only still present after any strata or covariates have
been accounted for in the computation of z scores. If strata or covariates remove the effective
aberrance between groups, the type-1 error rate is equivalent to that under H∩0 .
Aberrance in C ′1
For SNPs aberrant in C ′1, we have ζd = 0, ζc = 0, ζr 6= 0, ζs 6= 0 and ζm 6= 0.
Again, RA, RB, RC → P0 as ζr → 0. As ζr → ±∞, RA, RB, RC → α2 , and both are bounded
by α2 . Although RB and RC are typically higher than RA in this case, since both have the same
(typically conservative) upper bound, this is not typically a large sacrifice in type 1 error.
In the simplified case where γ = 1, an approximate upper bound on RB − RA is given by
(Appendix 1.4)
α
2
√
2pi
(
k√
1− ρ2 − 1
)
zβ  α
2
(9)
where
k =
ζs
ζr
≈
√
(n0 + n′0)(n′0 + n′1)
n′0(n0 + n′0 + n′1)
(10)
In practice, there is typically a similarly small difference between RC , RB and RA in the general
case.
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Aberrance in C ′0
For SNPs aberrant in C ′0, ζd = 0, ζr 6= 0, ζc 6= 0, ζs 6= 0 and ζm 6= 0. As for SNPs with aberrance
in C ′1, RA, RB, RC → P0 as ζr → 0 and as ζr → ±∞, RA, RB → α2 , both bounded above by α2 . RC ,
however, tends to 1 as ζd →∞.
In method B the cohort C0 has a correcting effect on the replication study, meaning |ζs| < |ζr|
and RB < RA.
For the simplified case where γ = 1, a similar bound to 9 holds for the difference RA − RB
(note signs are reversed) with
k′ =
ζs
ζr
≈
√
n′0(n′0 + n′1)
(n0 + n′0)(n0 + n′0 + n′1)
(11)
in the place of k. The improvement in type-1 error rate for a SNP with aberrance in C ′0 is generally
larger than the loss with the same aberrance in C ′1 (see methods), meaning that if aberrances are
of similar prevalence and size in C ′1 and C ′0, method B will typically have a lower type-1 error rate
than method A.
Aberrance in C0
Aberrance in C0 represents a serious problem in case-control study comparison. False-positive rates
are generally worse under method B, and tend to 1 as E(z) → ∞. If aberrances of this type are
expected to be very frequent, this may preclude use of methods B or C.
However, aberrances of this type may be best detected retrospectively by examining aberrances
between control groups at SNPs declared ‘hits’. This procedure is already a necessary quality-
control procedure in method A [13, 9], as method A does not provide any control over differences
between C0 and C
′
0. The number of SNPs reaching significance in the two-stage procedure is usually
small enough that this examination is readily tractable.
Aberrance in two or more cohorts
If SNPs are aberrant in both C1 and C
′
1, or in both C0 and C
′
0, the effect on RA and RB is
similar. If both cohorts are aberrant in the same direction, there is no way to differentiate the
SNP from a genuine association on the basis of the genotype data alone. If cohorts are aberrant
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in different directions, then in both methods, the type-1 error rate is lower than for a null SNP
with no aberration or aberration in only one cohort, as effect sizes for the discovery and replication
cohorts are biased in opposite directions. The same typically holds if C ′0 and C1, or C0 and C ′1, are
biased in the same direction.
If C ′0 and C ′1 or C0 and C1 are both biased in the same direction, RA is generally lower than
RB, as ζs 6= 0. Both RA and RB are bounded by α2 in this case. In addition, a systematic bias in
both replication groups (or both discovery groups) is likely to be due to a known confounder, the
effect of which can be removed by performing a stratified test (as is typically good practice when
confounders are known). Aberrance in opposite directions leads to RB > RA in the first case, and
a scenario similar to aberrance in C0 in the second case.
Aberrance in three or more cohorts corresponds to a chaotic scenario in which neither methods
A,B, or C will reliably provide FPR control. Aberrance of this extent is typically detectable and
removable using quality control procedures.
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Figure 4: Replication with shared controls. Red and blue shaded areas are regions where a pair of
observed Z scores are deemed a ‘hit’ in the (+,+) quadrant under method A/B respectively. The
value zm is almost linearly dependent on (zd, zr) and on (zd, zs) (Appendix 1.1). Solid red/blue
ellipses indicate contours of the distribution of observed Z scores for a typical non-null SNP under
methods A and B, and dashed ellipses indicate contours for a null SNP.
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Figure 5: Power difference (%) between methods C and A. Mean power difference is taken as the
integral of power difference between methods (see methods section) over R with respect to log-
odds ratio. In all cases, 20 000 samples are used overall for a SNP with MAF 0.1, with cutoffs
α = 5× 10−6, β = 5× 10−4, γ = 5× 10−8. Method C is almost universally more powerful.
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Figure 6: Power difference (%) between methods C and B. Mean power difference is taken as the
integral of power difference between methods (see methods section) over R with respect to log-
odds ratio. In all cases, 20 000 samples are used overall for a SNP with MAF 0.1, with cutoffs
α = 5× 10−6, β = 5× 10−4, γ = 5× 10−8.
25
1 Appendices
1.1 Covariance between Z scores due to shared samples
The matching of type-1 error rates between methods relies on establishing the covariance between
triples of z-scores under H∩0 . The covariance can be readily approximated when z-scores are as-
sumed to be derived from tests of equality of binomial random variables mi. Z-scores comparing
proportions without using additional information (such as strata or covariates) which are monotonic
to allelic difference and asymptotically have N(0, 1) distribution must be asymptotically equivalent
to those derived from binomial comparisons, so this assumption is reasonable.
If strata or covariates are used, either an assumption must be made that computed z-scores are
well-approximated by comparisons of binomial proportions, or correlations must be approximated
allowing for the covariate or strata structure. This is sometimes tractable analytically, but can also
be estimated empirically either by using known non-associated variants or by simulating variants
with the same covariate structure.
The presence of strata or covariates also affects the values ζi, and if the effects of covariates are
large, the approximations in equations 6 in the main paper may be poor. Values ζi can be estimated
as functions of allelic differences by simulating variants with the same covariate structure.
1.1.1 No covariates or stratification
Assume study i and j have ni0, n
j
0 controls and n
i
1, n
j
1 cases respectively, of which n
ij
0 controls
and nij1 cases are shared between both studies. Let m0,m1,m
′
0,m
′
1, denote the observed allele
frequencies of a SNP in the respective cohort, and µ0, µ1, µ
′
0, µ
′
1 the expected allele frequency.
If no strata or covariates are used in the calculation of summary statistics, z scores zd, zr, zs, zm
are asymptotically proportional to the allelic differences m1 − m0, m′1 − m′0, m′1 − m
′
0n
′
0+m0n0
n0+n′0
,
m1n1+m′1n
′
1
n1+n′1
− m′0n′0+m0n0
n0+n′0
respectively, since z scores are monotonic with allelic differences and allelic
differences are asymptotically normal. Since m0,m1,m
′
0,m
′
1 are independent and asymptotically
normal the multivariate random variables (zd, zr, zm) and (zd, zs, zm) have multivariate normal
distributions.
For studies i on n0i, n1i controls and cases and j on n0j , n1j controls and cases in which n0ij
and n1ij controls and cases are shared between studies, the correlation between the observed allelic
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differences m1i −m0i, m1j −m0j is given by
cor(m1i −m0i,m1j −m0j) = n0in0jn1ij + n1in1jn0ij
n0in0jn1in1j
√
1
n0i
+ 1n0j
√
1
n0j
+ 1n1j
(12)
This holds under H∩0 and approximately holds in general. Expressions for ρds, ρdm, ρrm and ρsm
may be derived in terms of n0, n1, n
′
0, and n
′
1. Specifically
det(ΣA) = 1− ρ2dm − ρ2rm
=
(n0n
′
1 − n′0n1)2
(n0 + n′0)(n1 + n′1)(n0 + n1)(n′0 + n′1)
(13)
det(ΣB) = 1− ρ2dm − ρ2ds − ρ2sm + 2ρdmρdsρsm
=
n′0n21
(n0 + n1)(n0 + n′0 + n′1)(n1 + n′1)
(14)
so ΣA is singular if
n0
n1
=
n′0
n′1
, and ΣB if n
′
0n1 = 0.
1.1.2 Z scores with stratification
If computation of Z scores is performed with correction for strata or covariates, formula 12 will not
asymptotically hold and may be a poor approximation to the true covariance. The true covariance
can be computed in some cases.
If samples are divided into strata 1, 2, ...s, and nrpq, m
r
pq, µ
r
pq denote the number of samples and
observed and expected minor allele frequencies in cohort p, study q, stratum r respectively, then
the z score zi for study q = i is asymptotically given by
zi =
∑
r∈1..s
αir (m
r
1i −mr0i) (15)
for positive values αir depending on the values n
r
pi. If the Cochran-Mantel-Hanszel test is used,
then
αir ∝ n
r
0in
r
1i
nr0i + n
r
1i
(16)
Suppose that nr0ij controls and n
r
1ij cases are shared between studies i and j in stratum r. Since
the values mrpq are dependent only within the same values of p and r, the correlation between zi
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and zj under the null hypothesis µ
r
0i ≡ µr1i, µr0i ≡ µr1i is given by
cor(zi, zj) =
∑
αirαjrcov(m
r
1i −mr0i,mr1j −mr0j)√
var(mr1i −mr0i)var(mr1j −mr0j)
≈
∑
r∈1..s α
(
nr0ij
nr0in
r
0j
+
nr1ij
nr1in
r
1j
)
√(∑
α2ir
(
1
nr0i
+ 1nr1i
))(∑
α2jr
(
1
nr0j
+ 1nr1j
)) (17)
where all sums are over the values of r ∈ 1..s for which the relevant values of nrpq are positive.
1.1.3 Z scores with covariates
If z scores are computed adjusting for one or more covariates, the estimation of correlation is more
difficult.
Assume that in a case population C1 and a control population C0 the values of some covariate(s)
x have different known distributions f1, f0, and that genotypes g at some SNP of interest may vary
with x. We will assume the populations are large and that f1, f0, and E(g|x) are continuous
functions of x.
Let gkp denote the genotype of individual k in cohort p (p ∈ C0, C1) and xkp denote covariate
value(s), where gkp is an observation of a random variable g. An idealised z-score testing association
of g with case/control status should be monotonic with each gkp and have expectation 0 if x is
independent of case/control status, whatever the form of the function E(g|x). Because individual
genotypes are assumed to be independent between individuals, cross-terms of the form
∏
i gi should
carry no additional information from singleton genotypes. We thus assume that z can thus be
decomposed into a weighted linear sum of individual genotypes:
z ∝ 1|C1|
∑
k∈C1
ck1g
k
1 −
1
|C0|
∑
k∈C0
ck0g
k
0 (18)
where the (positive) values ck1, c
k
0 depend only on the values x
·
1, x
·
0; that is, not on the relationship
between g and x, and the constant of proportionality depends on only on the observed allele
frequency. Let function c0(x), c1(x) denote the values of ci corresponding to covariate value(s) x in
C0, C1.
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For a null SNP, E(g|x) is independent of case/control status, but may take any (continuous)
form. We have
E(z) ∝ E
 1
|C1|
∑
i∈C1
cigi − 1|C0|
∑
i∈C0
cigi

lim
|C0|,|C1|→∞
E(z) ∝
∫
c1(x)f1(x)E(g|x)dx−
∫
c0(x)f0(x)E(g|x)
∝
∫
(c1(x)f1(x)− c0(x)f0(x))E(g|x)dx (19)
From a standard result from the calculus of variations, this implies that
c1(x)f1(x)− c0(x)f0(x) ≡ 0 =⇒ c1(x) ∝ f(x)
f1(x)
, c0(x) ∝ f(x)
f0(x)
(20)
for some function f , so the values ck1, c
k
0 effectively reweight the contribution of individuals to a
common density f(x) across x. The procedure of weighting observation k in this way is analogous
to a limiting case of stratification, in which weights are defined by the frequency of stratum r (see
above). For a constant allelic difference across the range of x, the best common distribution to
‘map to’ does not depend on the relationship between g and x, and hence the best values of ci
should be constant for all functions E(g|x).
Let zq denote a z-score for study q; npq, fpq = fpq(x) and Cpq denote the number of samples,
density function of x, and set of samples in cohort p, study q; gipq and c
k
pq denote the normalised
genotype of sample k in cohort p, study q and its coefficient in zq; n0s, n1s, f0s, f1s and C
s
0 , C
s
1
the number of shared controls/cases between studies, the density of x amongst the shared samples,
and the sets of shared samples; and fq the common density function to which cases and controls
are weighted in study q (equation 20). Then
cov(zi, zj) ≈
1
n0in0j
∑
k∈Cs0 c
k
0ic
k
0j +
1
n1in1j
∑
k∈Cs1 c
k
1ic
k
1j√
1
n21i
∑
k∈C1i(c
k
1i)
2 + 1
n20i
∑
k∈C0i(c
k
0i)
2
√
1
n21j
∑
k∈C1j (c
k
1j)
2 + 1
n20j
∑
k∈C0j (c
k
0j)
2
(21)
→
n0s
n0in0j
∫
f0s(x)
fi(x)fj(x)
f0i(x)f0j(x)
dx+ n1sn1in1j
∫
f1s(x)
fi(x)fj(x)
f1i(x)f1j(x)dx√
1
n0i
∫ fi(x)2
f0i(x)
dx+ 1n1i
∫ fi(x)2
f1i(x)
dx
√
1
n0j
∫ fj(x)2
f0j(x)
dx+ 1n1j
∫ fj(x)2
f1j(x)
dx
(22)
with integrals over the domain of x, and the limit as sample sizes tend to infinity while ratios
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between them remain bounded.
Logistic regression models with continuous covariates can only model simple (generally linear)
relationships between ci and xi, and property 20 may not hold. If the values c
k
pq are known, the
correlation can be determined using equation 21. If not, some methods for estimating correlation
are outlined below.
1.1.4 Practical estimation of covariance
Although the asymptotic correlation between z scores may be intractable, as long as the z score
permits an expansion of the form 18, the correlation will be nearly invariant with allele frequency
and change only minimally for SNPs associated with the covariate.
In practical terms, one method to estimate the correlation between z scores is to simply use the
sample correlation at a set of variants presumed to be not associated with the main trait of interest.
This approach may be unreliable and have limited power due to the difficulty of identifying such
variants
Another option is to permute existing genotypes without permuting covariates, and compute
correlation between resultant z scores. This has the disadvantage that it is difficult to permute
whilst maintaining potential relationships between genotypes and confounders.
Since the correlation should only depend on the sample sizes and structure of covariate distribu-
tions, a more convenient and powerful method is to simply simulate sets of genotypes unassociated
with the trait, but potentially associated with covariates in a range of different ways, and compute
correlation between the resultant z scores. Given the shortcomings of standard methods such as
logistic regression in fully accounting for covariate effects, this is an advisable procedure in any
analysis including covariates.
All results in the main paper which require conditions on sample sizes are only approximate
when using studies with stratification or covariates, with the approximation worsening with greater
differences in covariate values between groups and lower effective sample sizes.
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1.2 Properties of β∗
1.2.1 Asymptotic properties of β∗
In this appendix, an asymptotic approximation is established for β∗and it is shown that β∗ > β for
all ni0, n
j
0, n
i
1, n
j
1, zα, zγ . Define ΣA and ΣB as per equations 1 in the main paper, and note that
ΣA and ΣB only differ in their middle row/column. Further define
Σdm = var
(
(zd zm)
t|H∪0
)
=
 1 ρdm
ρdm 1
 (23)
Let (z′α z′γ) be the point in {zd > zα, zm > zγ} at minimal Mahalanobis distance from the origin
with respect to Σdm (ie, minimal (zd zm)Σ
−1
dm(zd zm)
t). Then for z′γ − ρdmz′α held constant, we have
lim
z′γ→∞/z′α→∞
√|ΣA| ((ρdsρdm − ρsm)z′γ + (ρdmρsm − ρds)z′α + |Σdm|zβ∗)√|ΣB| (−ρrmz′γ + ρdmρrmz′α + |Σdm|zβ) = 1 (24)
Specifically, for β∗ defined as per equation 3, we have
lim
α→0
zβ∗√
1− ρ2dszβ + ρdszα
= 1 (25)
and zβ∗ > max(β,
√
1− ρ2dszβ + ρzα) for all zα. Firstly the following lemma and corollary are
established:
Lemma 1. Let Σ be a positive definite matrix of dimension N , x be the vector (x1 x2...xn)
t, A1,
A0, and Z = (z1 z2...zn)
t constant vectors of dimension N with A1 6= A0 6= 0, C0 a constant, and
R the (closed) region x1 ≥ z1, x2 ≥ z2, , , xN ≥ zN .
Define C as the (unique) value satisfying
∫
R
e−
1
2
xtΣ−1x (Φ(At1x + C)− Φ(At0x + C0)) dx1dx2...dxN = 0 (26)
Denote y = (y1 y2...yN ) as the point in R at minimal Mahalanobis distance M(y) from the origin
with respect to Σ (usually, y = Z). Consider all regions R for which the corresponding value of y
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lies on the hyperplane At0y + C
′
0 = 0, C
′
0 6= C0. Then
lim
M(y)→∞|At0y+C′0=0
At1y + C
At0y + C0
= lim
M(y)→∞|At0y+C′0=0
At1y + C
C0 − C ′0
= 1 (27)
Proof. The value C is unique since the function Φ(At1x + C) is continuous and monotonically
increasing in C for all x, and hence so is the integrand (and integral).
We proceed from the formal definition of a limit
∀  > 0 ∃Y |
(
M(y) > Y =⇒
∣∣∣∣ At1y + CAt0y + C0 − 1
∣∣∣∣ < ) (28)
Because At0y + C
′
0 = 0, the right-hand side is equivalent to
(1− )(C0 − C ′0)−At1y ≤ C ≤ (1 + )(C0 − C ′0)−At1y (29)
We will show that there exists Y such that M(y) > Y implies that when C takes values at the
endpoints of the interval in the integral 29, the integral 26 takes different signs. Since the integral
is increasing in C and must be 0, C must lie in the interval in 29 for M(y) > Y .
If C takes the upper value, then at x = y, the value of the integrand is
e−
1
2
M(y)
(
Φ((1 + )(C0 − C ′0))− Φ(C0 − C ′0)
)
(30)
the sign of which depends on the sign of C0 − C ′0. We shall assume it is positive (with analogous
arguments if it is negative). Because  > 0, point y does not lie on the hyperplane (At1 −At0)x +
(1 + )(C0 − C ′0)−At1y − C0 = 0 (on which the integrand of 26 is 0). The distance from y to the
hyperplane is given by
D =
|(At1 −At0)y + (1 + )(C0 − C ′0)−At1y − C0|
||At1 −At0||
=
|(1 + )(C0 − C ′0)− C0 − C ′0|
||At1 −At0||
(31)
which is independent of y. Consider a hypersphere centred at y of radius d < D. Each point in
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the hypersphere can be expressed as y + κ with |κ| ≤ d, so within the hypersphere we have
Φ(At1x + C)− Φ(At0x + C0) = Φ(At1(y + κ) + (1 + )(C0 − C ′0)−At1y)
− Φ(At0(y + κ) + C0)
= Φ
(
(1 + )(C0 − C ′0) + At1κ
)
+ Φ
(
(C0 − C ′0) + At0κ
)
≥ Φ ((1 + )(C0 − C ′0) + |At1|d)
+ Φ
(
(C0 − C ′0)− |At0|d
)
(32)
Thus d can be chosen independently of y such that Φ(At1x+C)−Φ(At0x+C0) is bounded below in
the hypersphere by a constant X also independent of y. The function Φ(At1x +C)−Φ(At0x +C0)
is obviously bounded by ±2. Let R′ be the intersection of R and the hypersphere. The integral 26
now satisfies
∫
R
e−
1
2
xtΣ−1x (Φ(At1x + C)− Φ(At0x + C0)) dx1dx2...dxN
=
∫
R′
e−
1
2
xtΣ−1x (Φ(At1x + C)− Φ(At0x + C0)) dx1dx2...dxN
+
∫
R\R′
e−
1
2
xtΣ−1x (Φ(At1x + C)− Φ(At0x + C0)) dx1dx2...dxN
> X
∫
R′
e−
1
2
xtΣ−1xdx1dx2...dxN
− 2
∫
R\R′
e−
1
2
xtΣ−1xdx1dx2...dxN (33)
Because d (the radius of the hypersphere) does not depend on y, by the properties of the Gaussian
integral a value M+ can be chosen such that M(y) > M+ implies that the ratio
∫
R′ e
− 1
2
xtΣ−1xdx1dx2...dxN∫
R\R′ e
− 1
2
xtΣ−1xdx1dx2...dxN
(34)
is arbitrarily large (namely, > 2/X), and hence integral 33 is positive. In a similar way, a value
M− can be chosen such that if C takes the lower value of interval 29, the integral is negative for
M(y) > M−. For M(y) > max(M+,M−), the value of C satisfying equation 26 lies within the
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interval 29, and the limit is established.
Corollary 1. Given b, c, y ∈ R+, define a such that
∫ ∞
y
e−
x2
2 (Φ(c)− Φ(a− bx)) dx = 0 (35)
then
lim
y→∞
a
by + c
= 1 (36)
and a > by + c ∀ y
Proof. We note firstly that the function Φ(c)−Φ(a− bx) is increasing for all x. If the integral is 0,
the (smooth) integrand must cross 0 at some finite x ∈ (y,∞), and hence its value at x = y must
be negative. As Φ is increasing, we have Φ(a− by) > Φ(c) =⇒ a > by + c
The proof of the limit proceeds in a similar way to the proof of the lemma above.
Now (recalling definition 2 in the main paper)
∫ ∞
zα
∫ ∞
zγ
∫ ∞
zβ∗
NΣB
(
(zd zs zm)
t
)
dzsdzmdzd
=
∫ ∞
zα
∫ ∞
zγ
∫ ∞
zβ
NΣA
(
(zd zr zm)
t
)
dzrdzmdzd
=⇒
∫ ∞
zα
∫ ∞
zγ
NΣdm
(
(zd zm)
t
)
(Φ (a1zd + b1zm + c1)
−Φ (a0zd + b0zm + c0)) dzddzm = 0 (37)
34
where
a0 = − ρdmρrm√|Σdm||ΣA|
b0 =
ρrm√|Σdm||ΣA|
c0 = −
√
|Σdm|
|ΣA| zβ
a1 =
ρds − ρdmρsm√|Σdm||ΣB|
b1 =
ρsm − ρdsρdm√|Σdm||ΣB|
c0 = −
√
|Σdm|
|ΣB| zβ
∗ (38)
The asymptotic property of β∗ follows from corollary 1.
If γ = 1, we have from definition 3 in the main paper
∫ ∞
zα
∫ ∞
zβ∗
1
2pi
√
1− ρ2ds
exp
(
− 1
2(1− ρ2ds)
(
x2 + y2 − 2ρxy)) dxdy
=
∫ ∞
zα
∫ ∞
zβ
1
2pi
exp
(
−1
2
(
x2 + y2
))
dxdy
=⇒
∫ ∞
zα
e−
y2
2 Φ
zβ∗ − ρdsy√
1− ρ2ds
 dy = ∫ ∞
zα
e−
y2
2 Φ(zβ) (39)
from which the result follows from an application of lemma 1.
1.2.2 Size of β, β∗ and β⊥
To show that β∗ < β, we show that if we set zβ∗ = zβ in the integral 37, then the integral is
positive. Since it is decreasing with z∗β (as Φ is increasing) we must have z
∗
β > zβ if the integral is
to be 0. A similar argument can be used to show that β⊥ < β∗. Denote by I(zd, zm) the value of
the integrand of 37 with zβ∗ = zβ.
Consider the line a1zd+b1zm+c1 = a0zd+b0zm+c0 on the (zd, zm) plane on which the integrand
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of 37 is 0. The gradient of this line is
a0 − a1
b0 − b1 =
√
ni0(n0 + n
′
0)n1(n0 + n1)√
(n1 + n′1)(n0 + n′0 + n1 + n′1)
× (40)
n′0n1(n0 + n′0 + n1 + n′1)− (n0 + n′0)|n′0n1 − n0n′1|
n′0(n0 + n′0)n1(n0 + n1)− (n20 + n0n′0 + n′0n1)|n′0n1 − n0n′1|
(41)
Since |n′0n1 − n0n′1| ≥ (n′0n1 − n0n′1) the numerator of the second fraction is greater than or equal
to
n′0n1(n0 + n
′
0 + n1 + n
′
1)− (n0 + n′0)(n′0n1 − n0n′1) = n20n′1 + n′0(n21 + n0n′1 + n1n′1)
> 0 (42)
and similarly the denominator is greater than or equal to
n0(n
2
0n
′
1 + n
′
0(n
2
1 + n0n
′
1 + n1n
′
1)) > 0 (43)
so the gradient is positive. If b1 − b0 > 0, I(zd, zm) is positive if (zd, zm) falls above the line, and
negative if below it; if b1− b0 < 0, the other way around. Assume for the moment that b1− b0 < 0.
If the point (zα, zγ) lies above the line, then since I(zd, zm) is negative in the region (−∞, zα)×
(zγ ,∞), we have
∫ ∞
zα
∫ ∞
zγ
I(zd, zm)dzddzm ≥
∫ ∞
zα
∫ ∞
zγ
I(zd, zm)dzddzm
+
∫ zα
−∞
∫ ∞
zγ
I(zd, zm)dzddzm
=
∫ ∞
∞
∫ ∞
zγ
I(zd, zm)dzddzm (44)
If the point lies below the line, let z′γ > zγ be defined such that the point (zα, z′γ) lies on the line.
Since I(zd, zm) is positive in the region (zα,∞) × (zγ , z′γ) and negative in the region (−∞, zα) ×
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(zγ ,∞), we have
∫ ∞
zα
∫ ∞
zγ
I(zd, zm)dzddzm ≥
∫ ∞
zα
∫ ∞
zγ
I(zd, zm)dzddzm
−
∫ ∞
zα
∫ z′γ
zγ
I(zd, zm)dzddzm
+
∫ zα
−∞
∫ ∞
z′γ
I(zd, zm)dzddzm
=
∫ ∞
−∞
∫ ∞
z′γ
I(zd, zm)dzddzm (45)
so it is sufficient to prove that the integral is positive when the range (zα,∞) is replaced with
(−∞,∞). Similar arguments can be used when b1 − b0 > 0, in which case it is sufficient to prove
positivity when zγ = 0.
This enables zd (or zm) to be integrated out, namely reducing to showing that
∫ ∞
zβ
∫ ∞
zγ
N( 1 ρsm
ρsm 1
)((zs zm)t)−N( 1 ρrm
ρrm 1
)((zs zm)t)dzmdzs > 0
⇔
∫ ∞
zβ
1
2pi
exp
(
1
2
z2s
)(
Φ
(
ρsmzs − zγ
1− ρ2sm
)
− Φ
(
ρrmzs − zγ
1− ρ2rm
))
> 0 (46)
The second part of the integrand is monotonically increasing in zs as ρsm > ρrm. Thus the integral
is minimised as zβ → −∞, at which the value is Φ(zγ), which is positive.
1.3 SNPs with aberrant allele frequency in one group
1.3.1 RB < RA for SNPs with aberrance in C1
If SNPs have aberrant MAF in C1 only, we have E(zd) = ζd 6= 0, E(zm) = ζm 6= 0 and E(zs) =
E(zr) = 0. As noted in the main text, as ζd → 0, RB, RA → P0 (equation 2 in the main paper) and
lim
ζd→∞
RB = lim
ζd→∞
(∫ ∞
zα−ζd
∫ ∞
zβ∗
∫ ∞
zγ−ζm
NΣB
(
(zd zs zm)
t
)
dzsdzmdzd
+
∫ ∞
zα+ζd
∫ ∞
zβ∗
∫ ∞
zγ+ζm
NΣB
(
(zd zs zm)
t
)
dzsdzmdzd
)
= Φ(−z∗β) =
β∗
2
(47)
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and similarly, RA → β2 , RB → β
∗
2 as ζd → ±∞, with β∗ < β as shown above. For β∗ defined
by 3 in the main paper, we show here that RA > RB for all ζd. For the more general definition of
β∗ (equation 2 in the main paper), the inequality RB < RA may not hold for all ζd. However, in
practice, the inequality holds for almost all ζd and any deviation is small and near ζd = 0.
Define the shorthand Nρ(x, y) as the value at (x, y) of the bivariate normal PDF with mean
( 00 ) and variance
(
1 ρ
ρ 1
)
, and erfc(x) = 2
(
1− Φ(√2x)) as the complementary error function. In
this section, ρ refers to ρds.
Consider the value RA − RB as a function of ζd. We will show that the partial derivative
δ
δζd
(RA −RB) is zero only when ζd = 0. Because RA − RB passes through the origin and is
asymptotically positive in both directions, it is positive for all ζd 6= 0. We have
RA −RB =
(∫ ∞
zβ
∫ ∞
zα−ζd
N0(x, y)dxdy −
∫ ∞
zβ∗
∫ ∞
zα−ζd
Nρ(x, y)dxdy
)
+
(∫ −zβ
−∞
∫ −zα+ζd
−∞
N0(x, y)dxdy −
∫ −zβ∗
−∞
∫ −zα+ζd
−∞
Nρ(x, y)dxdy
)
(48)
δ
δζd
(RA −RB) =
(∫ ∞
zβ
δ
δζd
∫ ∞
zα−ζd
N0(x, y)dxdy −
∫ ∞
zβ∗
δ
δζd
∫ ∞
zα−ζd
Nρ(x, y)dxdy
)
+
(∫ ∞
zβ
δ
δζd
∫ ∞
zα+ζd
N0(x, y)dxdy −
∫ ∞
zβ∗
δ
δζd
∫ ∞
zα+ζd
Nρ(x, y)dxdy
)
=
1
2
√
2pi
erfc
(
zβ√
2
)(
e−
1
2
(ζd−zα)2 − e− 12 (ζd+zα)2
)
− 1
2
√
2pi
(
e−
1
2
(ζd−zα)2erfc
(
zβ∗ + ρ(ζd − zα)√
2(1− ρ2)
)
− e− 12 (ζd+zα)2erfc
(
zβ∗ − ρ(ζd + zα)√
2(1− ρ2)
))
Showing that δδζd (RA −RB) > 0 when ζd > 0 is equivalent to showing that (a− b)− (pa− qb) > 0
where a = e−
1
2
(ζd−zα)2 , b = e−
1
2
(ζd+zα)
2
, p =
erfc
(
zβ∗+ρ(ζd−zα)√
2(1−ρ2)
)
erfc
(
zβ
2
) and q = erfc
(
zβ∗+ρ(ζd−zα)√
2(1−ρ2)
)
erfc
(
zβ
2
) .
Since (ζd − za)2 < (ζd + za)2 for ζd > 0, we have a > b. Because erfc is strictly decreasing, we
have p < q. Because δpδζd < 0, we have
p <
erfc
(
zβ∗−zα)√
2(1−ρ2)
)
erfc
( zβ
2
) < 1 (49)
where the second inequality arises because zβ∗ >
√
1− ρ2zβ + ρzα. Thus pa − qb < pa − pb =
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p(a− b) < a− b, and δδζd (RA −RB) > 0 as required.
1.4 Upper bound on RB −RA with aberrance in C ′1
For SNPs with aberrance in C ′1, we have E(zd) = 0, E(zr) = ζr 6= 0, E(zs) = ζs 6= 0 and
E(zm) = ζm 6= 0. As above RA, RB → P0 as ζr → 0, and by similar arguments to the section
above, RA, RB → α2 as ζr → ±∞.
For β∗ defined as per equation 3 in the main paper, it is possible to derive an approximate
(asymptotically accurate) upper bound on RB −RA, corresponding to the most serious increase in
FPR. The approach is not readily applied to the general definition of β∗, but again the difference
is typically small in practice.
To first order
ζs
ζr
=
(
µ′1−µ′0
SE(m′1−m′0)
)
 µ′1−µ0
SE
(
m′1−
m0n0+m
′
0n
′
0
n0+n
′
0
)
 =
√
(n0 + n′0)(n′0 + n′1
n′0(n0 + n′0 + n′1)
def
= k (50)
Now
RB −RA =
(∫ ∞
zβ∗−ζs
∫ ∞
zα
Nρ(x, y)dxdy −
∫ ∞
zβ−ζr
∫ ∞
zα
N0(x, y)dxdy
)
+
(∫ ∞
zβ∗+ζs
∫ ∞
zα
Nρ(x, y)dxdy −
∫ ∞
zβ+ζr
∫ ∞
zα
N0(x, y)dxdy
)
(51)
Define z+r , z
−
r such that
∫ ∞
z−r
∫ ∞
zα
N0(x, y)dxdy =
∫ ∞
zβ∗−ζs
∫ ∞
zα
Nρ(x, y)dxdy∫ ∞
z+r
∫ ∞
zα
N0(x, y)dxdy =
∫ ∞
zβ∗+ζs
∫ ∞
zα
Nρ(x, y)dxdy (52)
From equation 25 in Appendix 1.2.1, we have zβ∗−ζs ≈
√
1− ρ2z−r −ρzα and zβ∗+ζs ≈
√
1− ρ2z+r −
ρzα.
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Noting that
∫∞
a
∫∞
b N0(x, y)dxdy = Φ(−a)Φ(−b) and Φ(x) = 1− Φ(−x) we now have
RB −RA = Φ(−zα)
(
Φ(zβ − ζr)− Φ(z−r ) + Φ(zβ + ζr)− Φ(z+r )
)
(53)
Applying the identity Φ(−zα) = α2 and approximations z∗β ≈
√
1− ρ2zβ + ρzα, ζs ≈ kζr, yields
z−r ≈
zβ∗ − ζs + ρzα√
1− ρ2 ≈ zβ −
k√
1− ρ2 ζr
z+r ≈ zβ +
k1√
1− ρ2 z
′
0 (54)
RB −RA ≈ α
2
(
Φ
(
zβ − k√
1− ρ2 ζr
)
− Φ(zβ − ζr) + Φ
(
zβ +
k√
1− ρ2 ζr
)
− Φ(zβ + ζr)
)
(55)
Considered as a function of ζr, the value RB −RA will be 0 at ζr = 0 and tend to 0 as ζr → ±∞.
It will be maximised approximately at the points where Φ(zβ− ζr) or Φ(zβ + ζr) are changing most
rapidly; that is, ζr = ±zβ. At ζr = zβ, the contribution to the value RB − RA from the difference
Φ
(
zβ +
k√
1−ρ2 ζr
)
−Φ(zβ +ζr) is negligible (and similarly for the other difference when ζr = −zβ).
Using the first-order approximation for Φ(zβ − ζr) about ζr = zβ yields
max (RB −RA) ≈ α
2
√
2pi
(
k√
1− ρ2 − 1
)
zβ (56)
In general, this value is substantially less than α.
All instances of ‘approximately equal’ are asymptotic limits as za →∞ and n0, n0′ , n1, n′1 →∞
with z′0 held finite.
1.5 Aberrance in C ′0
For SNPs aberrant in C ′0, again E(zd) = 0, E(zr) = ζr 6= 0, E(zs) = ζs 6= 0 and E(zm) = ζm 6= 0.
As above RA, RB → P0 as ζr → 0, and RA, RB → α2 as ζr → ±∞. In this case, RB is typically less
than RA.
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1.6 General aberrance in replication cohorts
For β∗ defined according to 3 in the main paper, the increase in FPR RB − RA for method B for
a SNP with aberrance in C ′1 is generally smaller than the decrease in FPR RA − RB for a SNP
with a similarly-sized aberrance in C ′0, in that the integral of the difference over the range of ζr is
generally smaller in the former.
We define k as in the section above and k1 =
ζs
ζr
∣∣C ′0 aberrant = √ n′0(n′0+n′1)(n0+n′0)(n0+n′0+n′1) similarly.
Now for C ′0 aberrant
RA −RB ≈ α
2
(
Φ(zβ − ζr)− Φ
(
zβ − k1√
1− ρ2 ζr
)
+ Φ(zβ + ζr)− Φ
(
zβ +
k1√
1− ρ2 ζr
))
(57)
Since
∫ x
0 Φ(z)dz = xΦ(x) +
1√
2pi
(
e−
x2
2 − 1
)
, we have
∫ ∞
0
(Φ(h− z)− Φ(h− kz)) dz =
(
1− 1
k
)(
1√
2pi
e−
1
2
h2 + hΦ(h)
)
(58)∫ ∞
0
(Φ(h+ z)− Φ(h+ kz)) dz =
(
1− 1
k
)(
− 1√
2pi
e−
1
2
h2 + hΦ(−h)
)
(59)
Thus with aberrant C ′0
∫ ∞
0
(RA −RB) dζr = α
2
(
1−
√
1− ρ2
k1
)
zβ (60)
Comparing RA and RB under the two aberrance scenarios with the same ζd
∫∞
0 (RA −RB) dζd [C ′0 aberrant]∫∞
0 (RB −RA) dζd [C ′1 aberrant]
=
1−
√
1−ρ2
k1√
1−ρ2
k − 1
(61)
For this to be > 1, a necessary condition is
(
1−
√
1−ρ2
k2
)
>
(√
1−ρ2
k1
− 1
)
From the definitions of
ρds (Appendix 1.1), k (equation 50) and k1, this is equivalent to
√
n0 + n′0 + n′1
n′0 + n′1
√
1− n0n1n
′
1
(n0 + n′0)(n0 + n1)(n0 + n′0 + n′1)
√ n′0
n0 + n′0
+
√
n0 + n′0
n0
 > 2
The final term in this product is of the form x + 1x so is greater than 2. A sufficient condition is
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thus
n0 + n
′
0 + n
′
1
n′0 + n′1
(
1− n0n1n
′
1
(n0 + n′0)(n0 + n1)(n0 + n′0 + n′1)
)
≥ 1
⇐⇒ n20 + n0(n′0 + n1) + n1(n′0 − n′1) ≥ 0 (62)
which holds in most study designs.
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